AKT1 and gastric cancer: This E542K mutation was present in GC tumors from patients with the greatest response to pan-Akt inhibitor capivasertib in the VIKTORY trial36, whereas the more resistant cell line in our study carried the E545K mutation, which was associated with less of a response in the VIKTORY trial.